Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes

医学 糖化血红素 甘精胰岛素 内科学 血糖性 临床终点 二甲双胍 糖尿病 胰岛素 2型糖尿病 安慰剂 内分泌学 胃肠病学 随机对照试验 病理 替代医学
作者
Dominik Dahl,Yukiko Onishi,Paul Norwood,Ruth Huh,Ross Bray,Hiren Patel,Ángel Rodríguez
出处
期刊:JAMA [American Medical Association]
卷期号:327 (6): 534-534 被引量:361
标识
DOI:10.1001/jama.2022.0078
摘要

Importance

The effects of tirzepatide, a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, as an addition to insulin glargine for treatment of type 2 diabetes have not been described.

Objective

To assess the efficacy and safety of tirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control.

Design, Setting, and Participants

Randomized phase 3 clinical trial conducted at 45 medical research centers and hospitals in 8 countries (enrollment from August 30, 2019, to March 20, 2020; follow-up completed January 13, 2021) in 475 adults with type 2 diabetes and inadequate glycemic control while treated with once-daily insulin glargine with or without metformin.

Interventions

Patients were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous injections of 5-mg (n = 116), 10-mg (n = 119), or 15-mg (n = 120) tirzepatide or volume-matched placebo (n = 120) over 40 weeks. Tirzepatide was initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until the assigned dose was achieved.

Main Outcomes and Measures

The primary end point was mean change from baseline in glycated hemoglobin A1c(HbA1c) at week 40. The 5 key secondary end points included mean change in body weight and percentage of patients achieving prespecified HbA1clevels.

Results

Among 475 randomized participants (211 [44%] women; mean [SD] age, 60.6 [9.9] years; mean [SD] HbA1c, 8.31% [0.85%]), 451 (94.9%) completed the trial. Treatment was prematurely discontinued by 10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide group, 18% in the 15-mg tirzepatide group, and 3% in the placebo group. At week 40, mean HbA1cchange from baseline was −2.40% with 10-mg tirzepatide and −2.34% with 15-mg tirzepatide vs −0.86% with placebo (10 mg: difference vs placebo, −1.53% [97.5% CI, −1.80% to −1.27%]; 15 mg: difference vs placebo, −1.47% [97.5% CI, −1.75% to −1.20%];P < .001 for both). Mean HbA1cchange from baseline was −2.11% with 5-mg tirzepatide (difference vs placebo, −1.24% [95% CI, −1.48% to −1.01%];P < .001]). Mean body weight change from baseline was −5.4 kg with 5-mg tirzepatide, −7.5 kg with 10-mg tirzepatide, −8.8 kg with 15-mg tirzepatide and 1.6 kg with placebo (5 mg: difference, −7.1 kg [95% CI, −8.7 to −5.4]; 10 mg: difference, −9.1 kg [95% CI, −10.7 to −7.5]; 15 mg: difference, −10.5 kg [95% CI, −12.1 to −8.8];P < .001 for all). Higher percentages of patients treated with tirzepatide vs those treated with placebo had HbA1cless than 7% (85%-90% vs 34%;P < .001 for all). The most common treatment-emergent adverse events in the tirzepatide groups vs placebo group were diarrhea (12%-21% vs 10%) and nausea (13%-18% vs 3%).

Conclusions and Relevance

Among patients with type 2 diabetes and inadequate glycemic control despite treatment with insulin glargine, the addition of subcutaneous tirzepatide, compared with placebo, to titrated insulin glargine resulted in statistically significant improvements in glycemic control after 40 weeks.

Trial Registration

ClinicalTrials.gov Identifier:NCT04039503
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
digger2023完成签到 ,获得积分10
22秒前
独特的沛凝完成签到,获得积分10
24秒前
王kk完成签到 ,获得积分10
26秒前
ljy2015完成签到 ,获得积分10
26秒前
木又完成签到 ,获得积分10
30秒前
aowulan完成签到 ,获得积分10
37秒前
冰凌心恋完成签到,获得积分10
52秒前
binyao2024完成签到,获得积分10
55秒前
Shrimp完成签到 ,获得积分10
57秒前
hr完成签到 ,获得积分10
59秒前
herococa应助继续加油吧采纳,获得10
1分钟前
xiaxiao完成签到,获得积分0
1分钟前
求助完成签到,获得积分10
1分钟前
白昼の月完成签到 ,获得积分0
1分钟前
coolkid应助科研通管家采纳,获得10
1分钟前
wanci应助科研通管家采纳,获得10
1分钟前
isedu完成签到,获得积分10
1分钟前
shezhinicheng完成签到 ,获得积分10
1分钟前
蟲先生完成签到 ,获得积分0
1分钟前
CNYDNZB完成签到 ,获得积分10
1分钟前
loren313完成签到,获得积分0
2分钟前
CYYDNDB完成签到 ,获得积分10
2分钟前
按照国际惯例完成签到 ,获得积分10
2分钟前
daisy0025完成签到,获得积分20
2分钟前
刘丰完成签到 ,获得积分10
2分钟前
铜豌豆完成签到 ,获得积分10
2分钟前
Amy完成签到 ,获得积分10
2分钟前
tianliyan完成签到 ,获得积分10
2分钟前
惊惶木完成签到 ,获得积分10
2分钟前
yunt完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
sweet雪儿妞妞完成签到 ,获得积分10
2分钟前
weinixiong3579完成签到,获得积分10
2分钟前
TanXu完成签到 ,获得积分10
2分钟前
南风完成签到 ,获得积分10
2分钟前
daisy0025关注了科研通微信公众号
3分钟前
小卷粉完成签到 ,获得积分10
3分钟前
青出于蓝蔡完成签到,获得积分10
3分钟前
cadcae完成签到,获得积分10
3分钟前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 1370
Secondary Ion Mass Spectrometry: Basic Concepts, Instrumental Aspects, Applications and Trends 1000
Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021 500
[Relativity of the 5-year follow-up period as a criterion for cured cancer] 500
Statistical Analysis of fMRI Data, second edition (Mit Press) 2nd ed 500
Huang‘s catheter ablation of cardiac arrthymias 5th edtion 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3940792
求助须知:如何正确求助?哪些是违规求助? 3486476
关于积分的说明 11037933
捐赠科研通 3216366
什么是DOI,文献DOI怎么找? 1777816
邀请新用户注册赠送积分活动 863828
科研通“疑难数据库(出版商)”最低求助积分说明 799036